bioRxivBioengineeringPreprint
Coronacept - a potent immunoadhesin against SARS-CoV-2
H. Cohen-Dvashi, J. Weinstein, M. Katz, M. Eilon, Y. Mor, A. Shimon, R. Strobelt, M. Shemesh, S. J. Fleishman, R. Diskin
Abstract
Angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Computational analysis of mammalian ACE2 orthologues suggests various residues at the interface with the viral receptor binding domain that could facilitate tighter interaction compared to the human-ACE2. Introducing several mutations to the human-ACE2 resulted with significantly augmented affinity to the viral spike complex. This modified human-ACE2 fused to an Fc portion of an antibody makes a potent immunoadhesin that effectively targets SARS-CoV-2.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- High affinity modified ACE2 receptors protect from SARS-CoV-2 infection in hamsters
Y. Higuchi, T. Suzuki, … A. Hoshino·bioRxiv·Sep 16, 2020
- Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2
H. Mou, B. Quinlan, … M. Farzan·bioRxiv·Jun 29, 2020
- Engineered ACE2 receptor traps potently neutralize SARS-CoV-2
A. Glasgow, J. E. Glasgow, … J. A. Wells·bioRxiv·Jul 31, 2020
- Computational simulations reveal the binding dynamics between human ACE2 and the receptor binding domain of SARS-CoV-2 spike protein
- The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2
E. Procko·bioRxiv·Mar 16, 2020
- ACE2 fragment as a decoy for novel SARS-Cov-2 virus
Fabiana Renzi, Dario Ghersi·bioRxiv·Apr 6, 2020